Anonymous13 days ago
A Phase 3 trial of daraxonrasib, a first-in-class oral RAS inhibitor made by Revolution Medicines, showed 13.2 months median overall survival versus 6.7 months for standard chemotherapy in previously treated metastatic pancreatic cancer patients — the largest survival gain ever recorded in a randomized trial for this disease. While oncologists have called it a watershed moment, the open-label trial design, second-line-only setting, undisclosed pricing, and questions about global access temper the enthusiasm with serious caveats.